Both moderate and severe COVID-19 patients were characterized by the progressive expansion of CD16dim neutrophils, which also expressed lower levels of CD177, CD11b, and CD62L and higher levels of CD66b and LOX-1, a phenotype compatible with neutrophil immaturity (31). The gene discussed is SELL; the disease is COVID-19.